Liver — guardian, modifier and target of sepsis

Key Points The liver represents a key integrator of microbial responses During microbial infection, the liver switches from tolerogenic towards immunogenic responses and initiates the production of acute-phase proteins Overwhelming inflammatory responses contribute to development of liver injury in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature reviews. Gastroenterology & hepatology 2017-01, Vol.14 (1), p.55-66
Hauptverfasser: Strnad, Pavel, Tacke, Frank, Koch, Alexander, Trautwein, Christian
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 66
container_issue 1
container_start_page 55
container_title Nature reviews. Gastroenterology & hepatology
container_volume 14
creator Strnad, Pavel
Tacke, Frank
Koch, Alexander
Trautwein, Christian
description Key Points The liver represents a key integrator of microbial responses During microbial infection, the liver switches from tolerogenic towards immunogenic responses and initiates the production of acute-phase proteins Overwhelming inflammatory responses contribute to development of liver injury in sepsis and to progression of acute-on-chronic liver failure in patients with liver cirrhosis Sepsis-induced liver injury comprises hypoxic hepatitis, sepsis-induced cholestasis and secondary sclerosing cholangitis of critically ill patients Patients with liver cirrhosis have an increased risk of microbial infections and are at high risk of death from sepsis, therefore, a fast and risk-adjusted antimicrobial therapy is important The liver regulates immune defence during sepsis, but is also a target for sepsis-related injury. Liver dysfunction can affect the prognosis of sepsis, particularly in patients with cirrhosis. In this Review, the importance of the liver in sepsis, the factors contributing to sepsis in patients with liver cirrhosis and new therapeutic strategies are discussed. Sepsis and septic shock are characterized by life-threatening organ dysfunction caused by a dysregulated host response to infection. The liver has a central role during sepsis, and is essential to the regulation of immune defence during systemic infections by mechanisms such as bacterial clearance, acute-phase protein or cytokine production and metabolic adaptation to inflammation. However, the liver is also a target for sepsis-related injury, including hypoxic hepatitis due to ischaemia and shock, cholestasis due to altered bile metabolism, hepatocellular injury due to drug toxicity or overwhelming inflammation, as well as distinct pathologies such as secondary sclerosing cholangitis in critically ill patients. Hence, hepatic dysfunction substantially impairs the prognosis of sepsis and serves as a powerful independent predictor of mortality in the intensive care unit. Sepsis is particularly problematic in patients with liver cirrhosis (who experience increased bacterial translocation from the gut and impaired microbial defence) as it can trigger acute-on-chronic liver failure — a syndrome with high short-term mortality. Here, we review the importance of the liver as a guardian, modifier and target of sepsis, the factors that contribute to sepsis in patients with liver cirrhosis and new therapeutic strategies.
doi_str_mv 10.1038/nrgastro.2016.168
format Article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_3143091209</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A474698409</galeid><sourcerecordid>A474698409</sourcerecordid><originalsourceid>FETCH-LOGICAL-c541t-9f5b0aa278594a1cc9a74578cfcd3c530060fed964e8f725b5b1d5a91c5551f73</originalsourceid><addsrcrecordid>eNp9kc1KxDAUhYMoOv48gBspCK6cMbfNbZvlIP7BgBtdh0ya1Mi0GZNWcOdD-IQ-idEZRwWVLBJuvnPuvRxC9oGOgGblSetrGTrvRimFfAR5uUYGUCAfIsVsffVmuEW2Q7inNEfM-CbZSgueMlrCgMDEPmqfvD6_JHUvfWVle5w0rrLGxrJsq6STvtZd4kwS9DzYsEs2jJwFvbe8d8jt-dnN6eVwcn1xdTqeDBUy6Ibc4JRKmRYlciZBKS4LhkWpjKoyhVkchhpd8Zzp0hQpTnEKFUoOChHBFNkOOVz4zr176HXoxL3rfRtbigxYRjmklP9HQYk5jwhPv6hazrSwrXGdl6qxQYkxK1jOS_bhNfqFiqfSjVWu1cbG-g_B0TfBnZaz7i64Wd9Z14afICxA5V0IXhsx97aR_kkAFe9Ris8oxXuUIkYZNQfLzfppo6uV4jO7CKQLIMSvttb-2-p_ur4Bs_uo-A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1856909392</pqid></control><display><type>article</type><title>Liver — guardian, modifier and target of sepsis</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Strnad, Pavel ; Tacke, Frank ; Koch, Alexander ; Trautwein, Christian</creator><creatorcontrib>Strnad, Pavel ; Tacke, Frank ; Koch, Alexander ; Trautwein, Christian</creatorcontrib><description>Key Points The liver represents a key integrator of microbial responses During microbial infection, the liver switches from tolerogenic towards immunogenic responses and initiates the production of acute-phase proteins Overwhelming inflammatory responses contribute to development of liver injury in sepsis and to progression of acute-on-chronic liver failure in patients with liver cirrhosis Sepsis-induced liver injury comprises hypoxic hepatitis, sepsis-induced cholestasis and secondary sclerosing cholangitis of critically ill patients Patients with liver cirrhosis have an increased risk of microbial infections and are at high risk of death from sepsis, therefore, a fast and risk-adjusted antimicrobial therapy is important The liver regulates immune defence during sepsis, but is also a target for sepsis-related injury. Liver dysfunction can affect the prognosis of sepsis, particularly in patients with cirrhosis. In this Review, the importance of the liver in sepsis, the factors contributing to sepsis in patients with liver cirrhosis and new therapeutic strategies are discussed. Sepsis and septic shock are characterized by life-threatening organ dysfunction caused by a dysregulated host response to infection. The liver has a central role during sepsis, and is essential to the regulation of immune defence during systemic infections by mechanisms such as bacterial clearance, acute-phase protein or cytokine production and metabolic adaptation to inflammation. However, the liver is also a target for sepsis-related injury, including hypoxic hepatitis due to ischaemia and shock, cholestasis due to altered bile metabolism, hepatocellular injury due to drug toxicity or overwhelming inflammation, as well as distinct pathologies such as secondary sclerosing cholangitis in critically ill patients. Hence, hepatic dysfunction substantially impairs the prognosis of sepsis and serves as a powerful independent predictor of mortality in the intensive care unit. Sepsis is particularly problematic in patients with liver cirrhosis (who experience increased bacterial translocation from the gut and impaired microbial defence) as it can trigger acute-on-chronic liver failure — a syndrome with high short-term mortality. Here, we review the importance of the liver as a guardian, modifier and target of sepsis, the factors that contribute to sepsis in patients with liver cirrhosis and new therapeutic strategies.</description><identifier>ISSN: 1759-5045</identifier><identifier>EISSN: 1759-5053</identifier><identifier>DOI: 10.1038/nrgastro.2016.168</identifier><identifier>PMID: 27924081</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/4020/2741/288 ; 692/4020/4021/1607/1604 ; 692/420/256/1980 ; 692/700/565 ; Acute phase proteins ; Acute-On-Chronic Liver Failure - etiology ; Anti-Bacterial Agents - therapeutic use ; Biomedicine ; Care and treatment ; Cholangitis ; Cholangitis, Sclerosing - etiology ; Cholestasis ; Cholestasis - etiology ; Chronic infection ; Cirrhosis ; Development and progression ; Gastroenterology ; Hepatitis ; Hepatology ; Humans ; Hypoxia ; Hypoxia - complications ; Immune response ; Immune system ; Immunogenicity ; Liver ; Liver - immunology ; Liver - injuries ; Liver cirrhosis ; Liver Cirrhosis - complications ; Liver diseases ; Medicine &amp; Public Health ; Observations ; Physiological aspects ; review-article ; Sepsis ; Sepsis - complications ; Sepsis - drug therapy ; Sepsis - immunology</subject><ispartof>Nature reviews. Gastroenterology &amp; hepatology, 2017-01, Vol.14 (1), p.55-66</ispartof><rights>Springer Nature Limited 2016</rights><rights>COPYRIGHT 2017 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Jan 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c541t-9f5b0aa278594a1cc9a74578cfcd3c530060fed964e8f725b5b1d5a91c5551f73</citedby><cites>FETCH-LOGICAL-c541t-9f5b0aa278594a1cc9a74578cfcd3c530060fed964e8f725b5b1d5a91c5551f73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/nrgastro.2016.168$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/nrgastro.2016.168$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27924081$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Strnad, Pavel</creatorcontrib><creatorcontrib>Tacke, Frank</creatorcontrib><creatorcontrib>Koch, Alexander</creatorcontrib><creatorcontrib>Trautwein, Christian</creatorcontrib><title>Liver — guardian, modifier and target of sepsis</title><title>Nature reviews. Gastroenterology &amp; hepatology</title><addtitle>Nat Rev Gastroenterol Hepatol</addtitle><addtitle>Nat Rev Gastroenterol Hepatol</addtitle><description>Key Points The liver represents a key integrator of microbial responses During microbial infection, the liver switches from tolerogenic towards immunogenic responses and initiates the production of acute-phase proteins Overwhelming inflammatory responses contribute to development of liver injury in sepsis and to progression of acute-on-chronic liver failure in patients with liver cirrhosis Sepsis-induced liver injury comprises hypoxic hepatitis, sepsis-induced cholestasis and secondary sclerosing cholangitis of critically ill patients Patients with liver cirrhosis have an increased risk of microbial infections and are at high risk of death from sepsis, therefore, a fast and risk-adjusted antimicrobial therapy is important The liver regulates immune defence during sepsis, but is also a target for sepsis-related injury. Liver dysfunction can affect the prognosis of sepsis, particularly in patients with cirrhosis. In this Review, the importance of the liver in sepsis, the factors contributing to sepsis in patients with liver cirrhosis and new therapeutic strategies are discussed. Sepsis and septic shock are characterized by life-threatening organ dysfunction caused by a dysregulated host response to infection. The liver has a central role during sepsis, and is essential to the regulation of immune defence during systemic infections by mechanisms such as bacterial clearance, acute-phase protein or cytokine production and metabolic adaptation to inflammation. However, the liver is also a target for sepsis-related injury, including hypoxic hepatitis due to ischaemia and shock, cholestasis due to altered bile metabolism, hepatocellular injury due to drug toxicity or overwhelming inflammation, as well as distinct pathologies such as secondary sclerosing cholangitis in critically ill patients. Hence, hepatic dysfunction substantially impairs the prognosis of sepsis and serves as a powerful independent predictor of mortality in the intensive care unit. Sepsis is particularly problematic in patients with liver cirrhosis (who experience increased bacterial translocation from the gut and impaired microbial defence) as it can trigger acute-on-chronic liver failure — a syndrome with high short-term mortality. Here, we review the importance of the liver as a guardian, modifier and target of sepsis, the factors that contribute to sepsis in patients with liver cirrhosis and new therapeutic strategies.</description><subject>692/4020/2741/288</subject><subject>692/4020/4021/1607/1604</subject><subject>692/420/256/1980</subject><subject>692/700/565</subject><subject>Acute phase proteins</subject><subject>Acute-On-Chronic Liver Failure - etiology</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Biomedicine</subject><subject>Care and treatment</subject><subject>Cholangitis</subject><subject>Cholangitis, Sclerosing - etiology</subject><subject>Cholestasis</subject><subject>Cholestasis - etiology</subject><subject>Chronic infection</subject><subject>Cirrhosis</subject><subject>Development and progression</subject><subject>Gastroenterology</subject><subject>Hepatitis</subject><subject>Hepatology</subject><subject>Humans</subject><subject>Hypoxia</subject><subject>Hypoxia - complications</subject><subject>Immune response</subject><subject>Immune system</subject><subject>Immunogenicity</subject><subject>Liver</subject><subject>Liver - immunology</subject><subject>Liver - injuries</subject><subject>Liver cirrhosis</subject><subject>Liver Cirrhosis - complications</subject><subject>Liver diseases</subject><subject>Medicine &amp; Public Health</subject><subject>Observations</subject><subject>Physiological aspects</subject><subject>review-article</subject><subject>Sepsis</subject><subject>Sepsis - complications</subject><subject>Sepsis - drug therapy</subject><subject>Sepsis - immunology</subject><issn>1759-5045</issn><issn>1759-5053</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kc1KxDAUhYMoOv48gBspCK6cMbfNbZvlIP7BgBtdh0ya1Mi0GZNWcOdD-IQ-idEZRwWVLBJuvnPuvRxC9oGOgGblSetrGTrvRimFfAR5uUYGUCAfIsVsffVmuEW2Q7inNEfM-CbZSgueMlrCgMDEPmqfvD6_JHUvfWVle5w0rrLGxrJsq6STvtZd4kwS9DzYsEs2jJwFvbe8d8jt-dnN6eVwcn1xdTqeDBUy6Ibc4JRKmRYlciZBKS4LhkWpjKoyhVkchhpd8Zzp0hQpTnEKFUoOChHBFNkOOVz4zr176HXoxL3rfRtbigxYRjmklP9HQYk5jwhPv6hazrSwrXGdl6qxQYkxK1jOS_bhNfqFiqfSjVWu1cbG-g_B0TfBnZaz7i64Wd9Z14afICxA5V0IXhsx97aR_kkAFe9Ris8oxXuUIkYZNQfLzfppo6uV4jO7CKQLIMSvttb-2-p_ur4Bs_uo-A</recordid><startdate>20170101</startdate><enddate>20170101</enddate><creator>Strnad, Pavel</creator><creator>Tacke, Frank</creator><creator>Koch, Alexander</creator><creator>Trautwein, Christian</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20170101</creationdate><title>Liver — guardian, modifier and target of sepsis</title><author>Strnad, Pavel ; Tacke, Frank ; Koch, Alexander ; Trautwein, Christian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c541t-9f5b0aa278594a1cc9a74578cfcd3c530060fed964e8f725b5b1d5a91c5551f73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>692/4020/2741/288</topic><topic>692/4020/4021/1607/1604</topic><topic>692/420/256/1980</topic><topic>692/700/565</topic><topic>Acute phase proteins</topic><topic>Acute-On-Chronic Liver Failure - etiology</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Biomedicine</topic><topic>Care and treatment</topic><topic>Cholangitis</topic><topic>Cholangitis, Sclerosing - etiology</topic><topic>Cholestasis</topic><topic>Cholestasis - etiology</topic><topic>Chronic infection</topic><topic>Cirrhosis</topic><topic>Development and progression</topic><topic>Gastroenterology</topic><topic>Hepatitis</topic><topic>Hepatology</topic><topic>Humans</topic><topic>Hypoxia</topic><topic>Hypoxia - complications</topic><topic>Immune response</topic><topic>Immune system</topic><topic>Immunogenicity</topic><topic>Liver</topic><topic>Liver - immunology</topic><topic>Liver - injuries</topic><topic>Liver cirrhosis</topic><topic>Liver Cirrhosis - complications</topic><topic>Liver diseases</topic><topic>Medicine &amp; Public Health</topic><topic>Observations</topic><topic>Physiological aspects</topic><topic>review-article</topic><topic>Sepsis</topic><topic>Sepsis - complications</topic><topic>Sepsis - drug therapy</topic><topic>Sepsis - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Strnad, Pavel</creatorcontrib><creatorcontrib>Tacke, Frank</creatorcontrib><creatorcontrib>Koch, Alexander</creatorcontrib><creatorcontrib>Trautwein, Christian</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Nature reviews. Gastroenterology &amp; hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Strnad, Pavel</au><au>Tacke, Frank</au><au>Koch, Alexander</au><au>Trautwein, Christian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Liver — guardian, modifier and target of sepsis</atitle><jtitle>Nature reviews. Gastroenterology &amp; hepatology</jtitle><stitle>Nat Rev Gastroenterol Hepatol</stitle><addtitle>Nat Rev Gastroenterol Hepatol</addtitle><date>2017-01-01</date><risdate>2017</risdate><volume>14</volume><issue>1</issue><spage>55</spage><epage>66</epage><pages>55-66</pages><issn>1759-5045</issn><eissn>1759-5053</eissn><abstract>Key Points The liver represents a key integrator of microbial responses During microbial infection, the liver switches from tolerogenic towards immunogenic responses and initiates the production of acute-phase proteins Overwhelming inflammatory responses contribute to development of liver injury in sepsis and to progression of acute-on-chronic liver failure in patients with liver cirrhosis Sepsis-induced liver injury comprises hypoxic hepatitis, sepsis-induced cholestasis and secondary sclerosing cholangitis of critically ill patients Patients with liver cirrhosis have an increased risk of microbial infections and are at high risk of death from sepsis, therefore, a fast and risk-adjusted antimicrobial therapy is important The liver regulates immune defence during sepsis, but is also a target for sepsis-related injury. Liver dysfunction can affect the prognosis of sepsis, particularly in patients with cirrhosis. In this Review, the importance of the liver in sepsis, the factors contributing to sepsis in patients with liver cirrhosis and new therapeutic strategies are discussed. Sepsis and septic shock are characterized by life-threatening organ dysfunction caused by a dysregulated host response to infection. The liver has a central role during sepsis, and is essential to the regulation of immune defence during systemic infections by mechanisms such as bacterial clearance, acute-phase protein or cytokine production and metabolic adaptation to inflammation. However, the liver is also a target for sepsis-related injury, including hypoxic hepatitis due to ischaemia and shock, cholestasis due to altered bile metabolism, hepatocellular injury due to drug toxicity or overwhelming inflammation, as well as distinct pathologies such as secondary sclerosing cholangitis in critically ill patients. Hence, hepatic dysfunction substantially impairs the prognosis of sepsis and serves as a powerful independent predictor of mortality in the intensive care unit. Sepsis is particularly problematic in patients with liver cirrhosis (who experience increased bacterial translocation from the gut and impaired microbial defence) as it can trigger acute-on-chronic liver failure — a syndrome with high short-term mortality. Here, we review the importance of the liver as a guardian, modifier and target of sepsis, the factors that contribute to sepsis in patients with liver cirrhosis and new therapeutic strategies.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>27924081</pmid><doi>10.1038/nrgastro.2016.168</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1759-5045
ispartof Nature reviews. Gastroenterology & hepatology, 2017-01, Vol.14 (1), p.55-66
issn 1759-5045
1759-5053
language eng
recordid cdi_proquest_journals_3143091209
source MEDLINE; SpringerLink Journals - AutoHoldings
subjects 692/4020/2741/288
692/4020/4021/1607/1604
692/420/256/1980
692/700/565
Acute phase proteins
Acute-On-Chronic Liver Failure - etiology
Anti-Bacterial Agents - therapeutic use
Biomedicine
Care and treatment
Cholangitis
Cholangitis, Sclerosing - etiology
Cholestasis
Cholestasis - etiology
Chronic infection
Cirrhosis
Development and progression
Gastroenterology
Hepatitis
Hepatology
Humans
Hypoxia
Hypoxia - complications
Immune response
Immune system
Immunogenicity
Liver
Liver - immunology
Liver - injuries
Liver cirrhosis
Liver Cirrhosis - complications
Liver diseases
Medicine & Public Health
Observations
Physiological aspects
review-article
Sepsis
Sepsis - complications
Sepsis - drug therapy
Sepsis - immunology
title Liver — guardian, modifier and target of sepsis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T09%3A33%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Liver%20%E2%80%94%20guardian,%20modifier%20and%20target%20of%20sepsis&rft.jtitle=Nature%20reviews.%20Gastroenterology%20&%20hepatology&rft.au=Strnad,%20Pavel&rft.date=2017-01-01&rft.volume=14&rft.issue=1&rft.spage=55&rft.epage=66&rft.pages=55-66&rft.issn=1759-5045&rft.eissn=1759-5053&rft_id=info:doi/10.1038/nrgastro.2016.168&rft_dat=%3Cgale_proqu%3EA474698409%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1856909392&rft_id=info:pmid/27924081&rft_galeid=A474698409&rfr_iscdi=true